Loofman is out makin' Jugs!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is two things I love in this life...
Old Loofman's Pure Kentucky Korn Licker and
Proxy Statements!
Jmo
Loofman
I had too many shares to keep track of anyway. Now thanks to Peregrine, I can again consume mass quantities of Pure Kentucky Korn Licker and not worry a lick about all them shares since they is gonna be a whole heap less!
Blessings,
Loofman
New Contest!
No rules. Winner gets a pat on the back.
Who's been in PPHM the longest?
1. Loofman 9 years
2.
$1.38 a share in 32.4 weeks. Me jug days so. It's real good at such things!
Jmo
Loofman
It's all good...
Ain't lost no more money since I lost the shed. The dog comes round ever now and again, and Tessi May don't hate me as much. Now I hopes that PPHM just gits a goin'! I figer I can hang in thar fer a far piece.
Jmo
Loofman
I give 6 jugs up fer that post opinion!
Off with them heads! I'm poorer than a skunk without a stinker. That's cause all them stinkers on the BOD took it all from us.
It's goin' to be a long and windin' road for the next couple of years. Glad I gots all my shares tucked safely away in my underwear drawer. Ain't nobody gonna look there. I just hope one of you will help me remember where I stuck 'em when that time comes to find 'em.
Just my opinion,
Loofman
This loony long continues to accumulate via mechanisims and prognostications based on regulated consumption of hard licker. I am slowly rebuilding my mass holdings in preparation for that glorious day still to come. There is no doubt in my mind I am going to recover from this addictive disease!
Jmo
Loofman
I waz a thinkin'...
I may just buy out Bavi fer a song and then add it to my Old Loofman's Pure Kentucky Korn Licker. I'll rename it, "Old Loofman's BathXXinatub." Sure to cure anything that ails you and makes yer skin feel smooth and silky. That is, if you can still feel it after consuming.
Jmo
Loofman
PPHMP
Stock Halt alert on Scottrade:
I think it has to do with this:
Trading in a stock will be paused for a minimum of five minutes, if the national best bid and offer (NBBO) price matches one of the upper or lower band limits for 15 seconds. A primary stock exchange can add another five minutes to the pause if necessary. The exchange also can halt trading at its discretion, if an NBBO price lies outside of the band limit. This is known as the straddle state. Under LU/LD if the national best bid (NBB) is priced below the lower band it will be non-executable. If the national best offer (NBO) is priced above the upper band it will be non-executable. Quotes outside the bands cannot be transacted against.
JMO
Loofman
CP...
Excellent. I value this post of yours more than any other that I have read. Well done. On the money.
I'm in a better mood today as I flipped a large position I purchased at .32 and sold today at .64. Now I'm only down 52 % overall on my overall investment. Lol
Loofman
Welcome to PPHM! It will be nice to have another long on board. Lol
Jmo
Loofman
I sure am glad a bought a whole heap of this here stock at .32 cents! Just doubled that chunk and now I can git the dawg back. Still workin' on the missus.
Loofman signing off fer now
Due to technical difficulties...
This ihub poster is off line until repairs are made.
I'm feeling a smite more optimistic like after drinking 6 jugs of Old Loofman's Pure Kentucky Korn Licker. I'ma thinkin' we wil go up to sompthin higher than what we is at now fer a spell. I need a roof and new winders real bad like.
Jmo
Loofman
Stone, you have clearly been a beneficiary to the therapeutic effects of Old Loofman's Pure Kentucky Korn Licker! Such positivity is an innate attribute of it's optisemal ambiance. PPHM always looks great while being under the spell of the fermented korn. I have enough of my licker to make it to October.
Best regards
Loofman
Solid point of view! I agree. Thanks for sharing.
Jmo
Loofman
To remind ourselves of Peregrine's connection to Dr. Wolchok and his laboratory through MSK.
TUSTIN, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development for the treatment of lung cancer, today announced that the company has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSK) to explore the potential of Peregrine's proprietary phosphatidylserine (PS)-targeting antibody platform. The goal of the research is to identify effective treatment combinations based on Peregrine's PS-targeting agents, including Peregrine's lead clinical agent bavituximab, with other checkpoint inhibitors or immune stimulating agents that will further guide the bavituximab clinical development program.
The studies at MSK will be performed under the direction of Taha Merghoub, Ph.D., Associate Attending Biologist, Melanoma and Immunotherapeutics Service, Ludwig Collaborative and the Swim Across America Laboratory, a part of the laboratory of Jedd D. Wolchok, M.D., Ph.D., a leader in the field of cancer immunotherapy. Dr. Wolchok serves as the Chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation as well as an Associate Director of the Ludwig Center for Cancer Immunotherapy at MSK.
"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Wolchok.
As part of the collaboration, researchers at MSK will conduct research to further explore the combination of PS-targeting agents, including bavituximab, that block a primary immunosuppressive pathway thereby allowing anti-tumor immune responses with other immuno-stimulatory agents that enhance immune responses. Specifically, MSK researchers will examine the combination of bavituximab alongside models of checkpoint blockade that are unresponsive to inhibition or co-stimulation given the ability of bavituximab to reprogram myeloid derived suppressor cells (MDSC) and increase tumoricidal T-cells in tumors, a mechanism of action that is complementary to checkpoint blockade and T-cell activation.
"A key focus of the Wolchok Lab's research is studying novel immunotherapy combinations that work together to enable the immune system to recognize and destroy cancer. This collaboration will allow us to focus on the role and contribution of PS blockade therapy in determining which combination of the current and next generation of immune modulators is likely to increase the extent and amplitude of anti-tumor response. This important pre-clinical and translational work will potentially guide the design of the next generation of clinical studies with bavituximab," said Dr. Merghoub.
"We are delighted to be working with a world-renowned pioneer and leader in the immuno-oncology space, recognizing that there remains significant research in order for more cancer patients to realize the benefits of combination immune therapy," said Jeff T. Hutchins, Ph.D., VP of Preclinical Research at Peregrine. "Our internal and collaborative research presented over the last year has established a robust foundation of PS-targeting activity on which to initiate this next chapter in PS research and development."
"This collaboration is an important extension of our established research efforts to further explore and understand the potential of our PS-targeting platform including bavituximab our lead clinical candidate. This research will focus on better understanding how treatment with PS-targeting agents can assist other anti-tumor immunotherapies in order to work better," said Steven King, chief executive officer of Peregrine. "Our goal is to change the way cancer patients are treated by allowing their immune system to recognize and fight their disease. This collaboration will undoubtedly assist us in identifying potential new opportunities to better treat patients with cancer."
Peregrine's antibodies target and bind to phosphatidylserine (PS), a highly immunosuppressive molecule normally located on the interior of cellular membranes, but, following stresses in the tumor environment, becomes exposed on tumor cells and cells that line tumor blood vessels, helping tumors to evade immune detection. PS-targeting antibodies block this immunosuppressive signal, thereby enabling the immune system to better recognize and fight the tumor. Preclinical data show that the combination of bavituximab and inhibitors of immune checkpoints reduce tumor-suppressive factors including myeloid-derived suppressor cells and confer increased tumor-specific immunity when compared to either treatment alone.
TO ALL:
I recommend everyone take a look at this news story called Hacking Cancer.
The upstream inhibitor that was use was not mentioned by name but...could it be the one we are hopeful for???
http://www.nbcnews.com/dateline
Jmo
Loofman
CP...why I asked about Wolchok is because NBC Dateline ran a story last night called Hacking Cancer.
The story's theme line is: "After losing a close friend to cancer, Silicon Valley billionaire Sean Parker decided he had to do something to help in the fight against the disease. His question: if you can hack a computer, could you hack cancer, too?"
The story went on to specifically discuss immunology and the research being done at MSK. In the story they interviewed patients who were stage 4 and had complete responses to an upstream checkpoint inhibitor. They are completely cured of cancer. The story goes on to interview Dr. Wolchok and describes his research as leading the way in immunology. There was no mention of Bavi, but it sure seemed like it could be a real player in the underlying story!
Below is the link to the story. It give me new and greatly revived hope for Peregrine and Bavimaxitub!!!!
http://www.nbcnews.com/dateline
Loofman
Does anyone know if ther is any connection between Jedd D. Wolchok, MD and Peregrine?
Just curious.
Loofman
It's about time I do something with it! Just bought it for 47 jugs of Old Loofman's Pure Kentucky Korn Licker. I am hoping that PPHM will git back up over a dollar so I can start Fixin' her up real nice like. Maybe Tessi May will come back home with the dawg then.
Jmo
Loofman
I want to thank you all for your responses to my question about your confidence in Peregrine. So far I have had 20 excellent responses. I appreciate every one of them, I really do!
I plan to keep this going and will look at this further this weekend. I plan to compile your thoughts.
Jmo
Loofman
I'm very serious about this...
I very much appreciate all who might respond to this request.
Please thoughtfully consider the following statement and add your alias to the list if you agree.
I still have confidence in Peregrine's management and this investment for the future?
1.
Only 5 months until the Peregrine Annual Shareholders Meeting!
Start making your plans now. It should be a raucous event full of energetic, inquiring shareholders!
Let them know well in advance that you will be attending so they can prepare a venue to hold everyone.
The meet and greet after the meeting should be super entertaining. I'm sure management will be impressed seeing so many of our faces in person.
Jmo
Loofman
With the current state of PPHM....
And my new financial situation, I'm looking fer a smite cheaper abode than my old place.
Hopefully they will come down a few dollars cause the price is still a bit high,
Jmo
Loofman
10 years and multi multi millions of dollars later...
Think I'll print out a 24x36 poster of this to hang over what's left of my fireplace.
Jmo
Loofman
CP, oversees is not the same as overseas in English. Oversee means to watch over, manage. Overseas means across the ocean. The word oversee was used a few times in the biography but refers to manage.
Looking at Avid alone in terms of valuation...
Does anyone have a bit of expertise in determining fair market value?
Am I even close to thinking 10x earnings going forward might be a reasonable assumption? I've lost my handle on what earnings may be. Would appreciate help with getting a number more pinned down.
I am also assuming that the pharma side of the business is going to be scaled down considerably in terms of payroll/positions with the emphasis now leaning on AZN collaboration and other IST's. Thus, drastically reducing trial expenses for Peregrine.
I also assume Peregrine will remain debt free and have very limited use of ATM.
So, if we can get a good handle on what Avid earnings might be and valuation based on what we know, we might be looking at PPHM turning a profit of some kind and hopefully a higher stock price down the road. ??
Thoughts?
Jmo
Loofman
We are the brotherhood of the Four P's!
We are the Piss Poor People of Peregrine!!
I hope you all have had an outstanding day and an even better tomorrow.
Loofman
Member PPPP
Since 2008
Have a great day all you good people.
And hopefully the hard working people of Peregrine are working harder than ever and their day will be good as well.
Loofman
I bet the 92 year old judge will decide to toss this case out the door once and for all. It might take a little time for him to send it out that door, but eventually, with the help of his cane he'll make it happen. The other judges will follow suit. Pun intended.
Jmo
Loofman
Yes indeed! Wouldn't it be really cool if we could buy all we want for 5 cents? Man...
I could more than double my holdings for only $4,500! What a rush that would be to have so many more shares.
Nothing like having more and more shares. I don't think I could thank management enough for that buying opportunity. I thought I was thankful for the .40 cent opportunity!
Jmo
Loofman
CP, I think you should go to find out why management has spent millions of dollars on trials that either were put on the shelf, were mishandled and failed before first look in because of futility. You should go to ask why there was no significant plan B ready to be in place after failed Phase lll trial which to this day has still not been revealed. You should go to ask management why they put all their eggs into one basket into an area where the signs were showing combinations with chemo were a declining area of potential and immunology was where science is heading.
There are at least 20 years worth of questions to ask of management in regards to creating shareholder value which management has stated it was attempting to do over all these years. The result ... 20 years later...
the vast majority of long term shareholders have lost on paper or in realuze losses 70, 80...90% of their investments under Peregrine managements ineffective control.
You deserve better, we deserve better. We all deserve transparency and honest answers as to how management plans to take the company forward in a measurable way that shows investiors fudiciary responsibility towards its shareholders. This does not include increased salaries, bonuses and cheap options.
Jmo
Loofman
From quarterly PR dated December 2012...
This was what management dangled before us after the bungled Bavi lung phase ll trial:
"Certainly the recent highlight for Peregrine is the agreement reached with the FDA that provides a clear pathway for advancing our Cotara program into a pivotal registration trial in patients with brain cancer. This milestone is the result of a significant amount of work and collaboration with the FDA of which we are particularly proud given the potential for this novel treatment in this difficult to treat disease," said Steven W. King, president and chief executive officer of Peregrine. "This was also a very strong quarter for our manufacturing subsidiary, Avid Bioservices, as we are on track for another record year of manufacturing revenues. We are also making steady progress in advancing the bavituximab program on multiple clinical fronts with important clinical milestones anticipated to occur over the coming months. Upcoming clinical milestones for the program include key median overall survival endpoints in pancreatic and front-line non-small cell lung cancer and final results from our second-line non-small cell lung cancer study in which we discovered discrepancies and have subsequently been intensely reviewing. The goal of this review is to be able to generate a final data set that we believe could be used to support advancing the program into a pivotal trial."
COTARA PROGRAM HIGHLIGHTS
Peregrine announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a single registration trial for Cotara in patients with recurrent glioblastoma multiforme (GBM) following an end-of-Phase II meeting. The FDA has agreed with the company's proposed randomized trial design evaluating two dose levels of Cotara in up to 300 patients. The trial design allows for multiple interim data analyses with the potential to stop patient accrual early based on predicted success or futility. The company plans to seek partners both in the U.S. and internationally to support the development of Cotara for this deadly form of brain cancer. Cotara has been granted orphan drug status and Fast Track designation for the treatment of GBM and anaplastic astrocytoma by the FDA and orphan drug designation by the European Medicines Agency (EMA)."
Makes you wonder what the heck???
Jmo
Loofman
I suppose if we really want to make our voices heard, it might be worth booking our flights and rooms now for the ASM. I would think if a few hundred of us show up at the meeting with great presence and loud voices, we might gain the board and management's attention? Wall to wall, floor to ceiling shareholders in attendance would certainly make for an interesting meeting.
Jmo
Loofman
How about...
Loofman sells all of his shares, loses nearly $100k, his still blows up but he manages to save 8 jugs of OLD LOOFMAN's PURE KENTUCKY KORN LICKER of which he has already consumed 3 of this morning and Tessi May dun left him fer good along with the dawg.
Loofman
Biopharm,
With respect to you, being optimistic is terribly difficult concerning Peregrine. Bfiest's recent conversation with IR confirms this. At this point and time, positive outcomes look to be years out. My only hope is a partner does understand the real potential of Bavi and offers fair market value for it, whatever that may be.
I have enough faith in Bavi, but not the people who run the company. Therefore we have a conundrum.
I don't like that much.
Jmo
Loofman
Regardless, I hope you have a happy one.
God works in mysterious ways. IMO, it's all for a reason which is out of our hands.
Be well...
Jmo,
Loofman
Our Mission
Delivering innovative and exceptional biopharmaceutical products to improve patient lives
Our Values:
Passion: We have a deep personal drive to improve patients’ lives
Innovation: We continuously pursue novel solutions
Integrity: We strive to do the right thing every time and accept responsibility for our actions
Teamwork: We foster collaboration and work together to achieve goals
Adaptability: We readily change to meet new challenges
Who is gonna be the poorest?
Based on the current situation with PPHM and lack of new information, direction and price support, I say this lends itself to a new contest...
(No rules. Winner gets nothing. Play at yer own risk. Frequent swigs of Korn licker allowed.)
1. Loofman - down $70k